Shots:

• Thermo Fisher to acquire QIAGEN in an all-cash transaction for $43.3/ share- making a total deal value ~$11.5B with a premium of 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on Mar 02- 2020. The transaction is expected to be completed in H1’21
• The focus of the acquisition is to expand Thermo Fisher’s specialty diagnostics portfolio with attractive molecular diagnostics capabilities- complements its life sciences offering with innovative sample preparation- assay and bioinformatics technologies and expand its customer access
• The acquisition provides Thermo Fisher an opportunity to leverage its capabilities and R&D expertise to accelerate innovation- addressing the emerging healthcare needs

Click here ­to­ read full press release/ article | Ref: Qiagen | Image: Wikipedia